-
1
-
-
43849085397
-
Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects
-
Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008;31:714-719
-
(2008)
Diabetes Care
, vol.31
, pp. 714-719
-
-
Juutilainen, A.1
Lehto, S.2
Rönnemaa, T.3
Pyörälä, K.4
Laakso, M.5
-
2
-
-
10344240901
-
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial
-
Quartet [corrected] Study Group.
-
Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 6068-6076
-
-
Schernthaner, G.1
Matthews, D.R.2
Charbonnel, B.3
Hanefeld, M.4
Brunetti, P.5
-
3
-
-
21344451651
-
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
-
Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48: 1093-1104
-
(2005)
Diabetologia
, vol.48
, pp. 1093-1104
-
-
Charbonnel, B.1
Schernthaner, G.2
Brunetti, P.3
-
4
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin pioglitazone and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
-
DURATION-4 Study Group.
-
Russell-Jones D, Cuddihy RM, Hanefeld M, et al.; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-258
-
(2012)
Diabetes Care
, vol.35
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
-
5
-
-
77957710722
-
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents
-
Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-1961
-
(2010)
Drugs
, vol.70
, pp. 1945-1961
-
-
Derosa, G.1
-
6
-
-
79953232077
-
Pioglitazone for diabetes prevention in impaired glucose tolerance
-
ACT NOW Study.
-
DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N EnglJ Med 2011;364:1104-1115
-
(2011)
N EnglJ Med
, vol.364
, pp. 1104-1115
-
-
Defronzo, R.A.1
Tripathy, D.2
Schwenke, D.C.3
-
7
-
-
0343485089
-
Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study
-
Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20:538-544
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 538-544
-
-
Pyörälä, M.1
Miettinen, H.2
Halonen, P.3
Laakso, M.4
Pyörälä, K.5
-
8
-
-
0036633043
-
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study
-
Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25:1135-1141
-
(2002)
Diabetes Care
, vol.25
, pp. 1135-1141
-
-
Bonora, E.1
Formentini, G.2
Calcaterra, F.3
-
9
-
-
33244464265
-
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review
-
Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-441
-
(2006)
Diabetologia
, vol.49
, pp. 434-441
-
-
Natali, A.1
Ferrannini, E.2
-
10
-
-
0022881373
-
Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus
-
Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986; 12:346-350
-
(1986)
Diabete Metab
, vol.12
, pp. 346-350
-
-
Prager, R.1
Schernthaner, G.2
Graf, H.3
-
12
-
-
77958529709
-
Cardiovascular risk and thiazolidinedionesdwhat do meta-analyses really tell us?
-
Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinedionesdwhat do meta-analyses really tell us? Diabetes Obes Metab 2010;12:1023-1035
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 1023-1035
-
-
Schernthaner, G.1
Chilton, R.J.2
-
13
-
-
35148837113
-
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
-
GLAI Study Investigators.
-
Deeg MA, Buse JB, Goldberg RB, et al.; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30: 2458-2464
-
(2007)
Diabetes Care
, vol.30
, pp. 2458-2464
-
-
Deeg, M.A.1
Buse, J.B.2
Goldberg, R.B.3
-
14
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304:411-418
-
(2010)
JAMA
, vol.304
, pp. 411-418
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
Macurdy, T.E.3
-
15
-
-
84872127720
-
A new "comparative Effectiveness" assessment strategy using the THIN database: Comparison of the cardiac complications of pioglitazone and rosiglitazone
-
Tannen R, Xie D, Wang X, Yu M, Weiner MG. A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 2013;22: 86-97
-
(2013)
Pharmacoepidemiol Drug Saf
, vol.22
, pp. 86-97
-
-
Tannen, R.1
Xie, D.2
Wang, X.3
Yu, M.4
Weiner, M.G.5
-
16
-
-
34250723983
-
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metfor-min
-
Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metfor-min. Hypertens Res 2007;30:387-394
-
(2007)
Hypertens Res
, vol.30
, pp. 387-394
-
-
Derosa, G.1
Fogari, E.2
Cicero, A.F.3
-
17
-
-
65649084066
-
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
-
Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009;63:912-929
-
(2009)
Int J Clin Pract
, vol.63
, pp. 912-929
-
-
Schernthaner, G.1
-
18
-
-
77957742069
-
Severe hypoglycemia and risks of vascular events and death
-
ADVANCE Collaborative Group.
-
Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
-
(2010)
N Engl J Med
, vol.363
, pp. 1410-1418
-
-
Zoungas, S.1
Patel, A.2
Chalmers, J.3
-
19
-
-
75749145810
-
Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study
-
Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2012;375:481-489
-
(2012)
Lancet
, vol.375
, pp. 481-489
-
-
Currie, C.J.1
Peters, J.R.2
Tynan, A.3
-
20
-
-
84862108594
-
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes
-
Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-1132
-
(2012)
Diabetes Care
, vol.35
, pp. 1126-1132
-
-
Zhao, Y.1
Campbell, C.R.2
Fonseca, V.3
Shi, L.4
-
21
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
-
PROactive investigators.
-
Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-1289
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
22
-
-
33847675510
-
The effect of pio-glitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study
-
PROactive Investigators.
-
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pio-glitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1772-1780
-
-
Erdmann, E.1
Dormandy, J.A.2
Charbonnel, B.3
Massi-Benedetti, M.4
Moules, I.K.5
Skene, A.M.6
-
23
-
-
33947539408
-
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
-
PROactive Investigators
-
Wilcox R, Bousser MG, Betteridge DJ, et al.; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-873
-
(2007)
Stroke
, vol.38
, pp. 865-873
-
-
Wilcox, R.1
Bousser, M.G.2
Betteridge, D.J.3
-
24
-
-
57649213646
-
Impact of peripheral arterial disease in patients with diabetesdresults from PROactive (PROactive 11)
-
PROactive investigators
-
Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators. Impact of peripheral arterial disease in patients with diabetesdresults from PROactive (PROactive 11). Atherosclerosis 2009;202:272-281
-
(2009)
Atherosclerosis
, vol.202
, pp. 272-281
-
-
Dormandy, J.A.1
Betteridge, D.J.2
Schernthaner, G.3
Pirags, V.4
Norgren, L.5
-
25
-
-
33845400193
-
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial
-
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581
-
(2006)
JAMA
, vol.296
, pp. 2572-2581
-
-
Mazzone, T.1
Meyer, P.M.2
Feinstein, S.B.3
-
26
-
-
41649084422
-
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
-
PERISCOPE Investigators
-
Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299: 1561-1573
-
(2008)
JAMA
, vol.299
, pp. 1561-1573
-
-
Nissen, S.E.1
Nicholls, S.J.2
Wolski, K.3
-
27
-
-
38149077162
-
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease
-
Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008;19:182-187
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 182-187
-
-
Schneider, C.A.1
Ferrannini, E.2
Defronzo, R.3
Schernthaner, G.4
Yates, J.5
Erdmann, E.6
-
28
-
-
64949086377
-
Thiazolidinedione use is associated with better survival in hemo-dialysis patients with non-insulin dependent diabetes
-
Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemo-dialysis patients with non-insulin dependent diabetes. Kidney Int 2009;75: 961-968
-
(2009)
Kidney Int
, vol.75
, pp. 961-968
-
-
Brunelli, S.M.1
Thadhani, R.2
Ikizler, T.A.3
Feldman, H.I.4
-
29
-
-
84860117993
-
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK General Practice Research Database
-
Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK General Practice Research Database. BMJ 2009;339:b4731
-
(2009)
BMJ
, vol.339
-
-
Tzoulaki, I.1
Molokhia, M.2
Curcin, V.3
-
30
-
-
34548590934
-
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
-
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188
-
(2007)
JAMA
, vol.298
, pp. 1180-1188
-
-
Lincoff, A.M.1
Wolski, K.2
Nicholls, S.J.3
Nissen, S.E.4
-
31
-
-
84866138849
-
Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials
-
Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603
-
(2012)
Diabetologia
, vol.55
, pp. 2593-2603
-
-
Stevens, R.J.1
Ali, R.2
Bankhead, C.R.3
-
33
-
-
84870753442
-
What next after metformin? A retrospective evalua-tionof the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes
-
Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evalua-tionof the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97: 4605-4612
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 4605-4612
-
-
Morgan, C.L.1
Poole, C.D.2
Evans, M.3
Barnett, A.H.4
Jenkins-Jones, S.5
Currie, C.J.6
-
34
-
-
84870248203
-
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population
-
Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol 2012;162:20-26
-
(2012)
Int J Cardiol
, vol.162
, pp. 20-26
-
-
Doehner, W.1
Erdmann, E.2
Cairns, R.3
-
35
-
-
50649121372
-
Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12, 772 patients in England
-
Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12, 772 patients in England. Drug Saf 2008;31:839-850
-
(2008)
Drug Saf
, vol.31
, pp. 839-850
-
-
Kasliwal, R.1
Wilton, L.V.2
Shakir, S.A.3
-
36
-
-
34648824645
-
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08)
-
PROactive investigators.
-
Erdmann E, Charbonnel B, Wilcox RG, et al.; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30: 2773-2778
-
(2007)
Diabetes Care
, vol.30
, pp. 2773-2778
-
-
Erdmann, E.1
Charbonnel, B.2
Wilcox, R.G.3
-
38
-
-
23844472901
-
Thiazoli-dinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption
-
Guan Y, Hao C, Cha DR, et al. Thiazoli-dinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-866
-
(2005)
Nat Med
, vol.11
, pp. 861-866
-
-
Guan, Y.1
Hao, C.2
Cha, D.R.3
-
39
-
-
79958816344
-
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
-
Betteridge DJ. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011;28:759-771
-
(2011)
Diabet Med
, vol.28
, pp. 759-771
-
-
Betteridge, D.J.1
-
40
-
-
84867571503
-
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
-
Scottish Diabetes Research Network Epidemiology Group.
-
Colhoun HM, Livingstone SJ, Looker HC, et al.; Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929-2937
-
(2012)
Diabetologia
, vol.55
, pp. 2929-2937
-
-
Colhoun, H.M.1
Livingstone, S.J.2
Looker, H.C.3
-
41
-
-
63849148589
-
Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive
-
PROactive investigators
-
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009;32: 187-202
-
(2009)
Drug Saf
, vol.32
, pp. 187-202
-
-
Dormandy, J.1
Bhattacharya, M.2
Van Troostenburg De Bruyn, A.R.3
-
42
-
-
58849094131
-
Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis
-
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-39
-
(2009)
CMAJ
, vol.180
, pp. 32-39
-
-
Loke, Y.K.1
Singh, S.2
Furberg, C.D.3
-
43
-
-
37749034527
-
Skeletal consequences of thiazoli-dinedione therapy
-
Grey A. Skeletal consequences of thiazoli-dinedione therapy. Osteoporos Int 2008; 19:129-137
-
(2008)
Osteoporos Int
, vol.19
, pp. 129-137
-
-
Grey, A.1
-
44
-
-
84863694353
-
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes
-
Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012;172:1005-1011
-
(2012)
Arch Intern Med
, vol.172
, pp. 1005-1011
-
-
Idris, I.1
Warren, G.2
Donnelly, R.3
-
45
-
-
62649174048
-
Glitazone use associated with diabetic macular edema
-
e1
-
Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147:583-586, e1
-
(2009)
Am J Ophthalmol
, vol.147
, pp. 583-586
-
-
Fong, D.S.1
Contreras, R.2
-
46
-
-
79960720836
-
-
Takeda Pharmaceuticals, Accessed 29 January 2013
-
Takeda Pharmaceuticals. Highlights of prescribing information [Internet], 2011. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021073s035lbl.pdf. Accessed 29 January 2013
-
(2011)
Highlights of Prescribing Information [Internet]
-
-
-
47
-
-
79956217900
-
Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study
-
Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922
-
(2011)
Diabetes Care
, vol.34
, pp. 916-922
-
-
Lewis, J.D.1
Ferrara, A.2
Peng, T.3
-
48
-
-
84891799937
-
-
Pioglitazone HCl. (ACTOS). Clinical study no. 01-03-TL-OPI-524. Cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 [article online], Accessed 15 March 2013
-
Pioglitazone HCl. (ACTOS). Clinical study no. 01-03-TL-OPI-524. Cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 [article online], 2011. Available from http://www.pharmatelligence.co.uk/ static/documents/01-03-tl-opi-524-8-year-interim-report.pdf. Accessed 15 March 2013
-
(2011)
-
-
-
49
-
-
84866358522
-
Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study
-
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55: 1953-1962
-
(2012)
Diabetologia
, vol.55
, pp. 1953-1962
-
-
Neumann, A.1
Weill, A.2
Ricordeau, P.3
Fagot, J.P.4
Alla, F.5
Allemand, H.6
-
50
-
-
84891752477
-
-
U.S. Food and Drug Administration. FDA Drug Safety Communication. update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [article online], Accessed 29 January 2013
-
U.S. Food and Drug Administration. FDA Drug Safety Communication. update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [article online], 2011. Available from http://www. fda.gov/drugs/ drugsafety/ucm259150.htm. Accessed 29 January 2013
-
(2011)
-
-
-
51
-
-
84862684037
-
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study
-
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344: e3645
-
(2012)
BMJ
, vol.344
-
-
Azoulay, L.1
Yin, H.2
Filion, K.B.3
-
52
-
-
84871113059
-
Pioglitazone and bladder cancer: A propensity score matched cohort study
-
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-259
-
(2013)
Br J Clin Pharmacol
, vol.75
, pp. 254-259
-
-
Wei, L.1
Macdonald, T.M.2
Mackenzie, I.S.3
-
53
-
-
84865858873
-
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis
-
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-E683
-
(2012)
CMAJ
, vol.184
-
-
Colmers, I.N.1
Bowker, S.L.2
Majumdar, S.R.3
Johnson, J.A.4
-
54
-
-
84867395333
-
Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
-
Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012;98:159-163
-
(2012)
Diabetes Res Clin Pract
, vol.98
, pp. 159-163
-
-
Zhu, Z.1
Shen, Z.2
Lu, Y.3
Zhong, S.4
Xu, C.5
-
55
-
-
84856101775
-
The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipid-emia, and gout in Taiwanese patients
-
Lee MY, Lin KD, Hsiao PJ, Shin SJ. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipid-emia, and gout in Taiwanese patients. Metabolism 2012;61:242-249
-
(2012)
Metabolism
, vol.61
, pp. 242-249
-
-
Lee, M.Y.1
Lin, K.D.2
Hsiao, P.J.3
Shin, S.J.4
-
56
-
-
84859760984
-
Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mel-litus
-
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mel-litus. Hepatology 2012;55:1462-1472
-
(2012)
Hepatology
, vol.55
, pp. 1462-1472
-
-
Chang, C.H.1
Lin, J.W.2
Wu, L.C.3
Lai, M.S.4
Chuang, L.M.5
Chan, K.A.6
-
57
-
-
84873859028
-
Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based, case-control study
-
Health Data Analysis in Taiwan Research Group.
-
Chen SW, Tsan YT, Chen JD, et al.; Health Data Analysis in Taiwan Research Group. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care 2013; 36:369-375
-
(2013)
Diabetes Care
, vol.36
, pp. 369-375
-
-
Chen, S.W.1
Tsan, Y.T.2
Chen, J.D.3
-
58
-
-
34248192254
-
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
-
Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25:1476-1481
-
(2007)
J Clin Oncol
, vol.25
, pp. 1476-1481
-
-
Govindarajan, R.1
Ratnasinghe, L.2
Simmons, D.L.3
-
59
-
-
84866156935
-
The effect of met-formin and thiazolidinedione use on lung cancer in diabetics
-
Mazzone PJ, Rai H, Beukemann M, Xu M, Jain AK, Sasidhar M. The effect of met-formin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012;12: 410
-
(2012)
BMC Cancer
, vol.12
, pp. 410
-
-
Mazzone, P.J.1
Rai, H.2
Beukemann, M.3
Xu, M.4
Jain, A.K.5
Sasidhar, M.6
|